Clinical trial
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or…
NCT00090012 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00090012 |
|---|---|
| Title | Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder |
| Official title | The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine, Quetiapine |
| Enrollment | 340 |
| Start date | Jul 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Aug 23, 2004 |
| Last update posted | Nov 6, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: